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Most antimalarial drugs face decreased efficacy due to the
emergence of resistant parasites. Therefore, the discovery
of new antimalarial medicines is focused on new drugs
that act by novel mechanisms and are active against differ-
ent P. falciparum development stages. Screening of a
focused compound library for antiparasitic activity, lead to
identification of a novel class of compounds with activity
against P. falciparum, 2-aminopyridines. The selected hits
were validated and subjected to a lead optimization pro-
gram resulting in the pre-clinical candidate MMV390048.
Here we report an unbiased chemoproteomics strategy for
the identification of targets of MMV390048. An analogue
of MMV390048 containing a primary amine function for
immobilization in a permissive position was synthesized
and covalently immobilized on sepharose beads. Affinity
capturing of potential target proteins from a P. falciparum
blood stage extract was performed in the absence and pre-
sence of an excess of MMV390048 in the extract to
delineate target proteins for which capturing is competi-
tively inhibited. All proteins captured by the beads were
quantified by isotope tagging of tryptic peptides followed
by LC-MS/MS. Notably MMV390048 competitively inhib-
ited the binding of only a single protein, P. falciparum PI4
kinase, to the beads. However, the immobilization of a
drug compound via a linker may not be compatible with
the binding to all of its targets. Therefore, we also per-
formed a capturing experiment with kinobeads, which
represent a combination of immobilized promiscuous
ATP competitive kinase inhibitors (Bantscheff et al.,
2007). As in the previous experiment, PfPI4K was the only
P. falciparum protein which exhibited a reduction of bead
binding upon the addition of MMV390048 to the extract.
Knowledge of the target will accelerate the drug discovery
process.
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